BACKGROUND: Adults with X-linked adrenoleukodystrophy (X-ALD) remain at risk for progressive neurological deterioration. Phenotypes vary in their pathology, ranging from axonal degeneration to inflammatory demyelination. The severity of symptoms is poorly explained by conventional imaging. OBJECTIVE: To test the hypothesis that neurochemistry in normal-appearing brains differs in adult phenotypes of X-ALD and that neurochemical changes correlate with the severity of symptoms. PATIENTS AND METHODS: Using a 7-Tesla scanner, we performed structural and proton magnetic resonance spectroscopic imaging in 13 adult patients with X-ALD: 4 patients with adult cerebral ALD, 5 patients with adrenomyeloneuropathy (AMN), and 4 female heterozygotes. Nine healthy controls were included. RESULTS: Among adult X-ALD phenotypes, the myo-inositol to creatine ratio was 46% higher and the choline to creatine ratio was 21% higher in normal-appearing white matter of those with adult cerebral ALD compared with those with AMN (P < .05). Both N-acetylaspartate to creatine (P = .03) and glutamate to creatine (P = .04) ratios were lower in AMN patients than in controls. There were no significant differences between patients with AMN and female heterozygotes. In the cortex, patients with adult cerebral ALD had lower N-acetylaspartate to creatine ratios compared with female heterozygotes and controls (P = .02). The global myo-inositol to creatine ratio demonstrated a significant association with Expanded Disability Status Scale score (Spearman rho = 0.66, P = .04). CONCLUSIONS: Seven-Tesla proton magnetic resonance spectroscopic imaging reveals differences in the neurochemistry of adult cerebral ALD but cannot distinguish AMN patients from female heterozygotes. Myo-inositol to creatine ratio correlates with the severity of the symptoms and may be a meaningful biomarker in adult X-ALD.
BACKGROUND: Adults with X-linked adrenoleukodystrophy (X-ALD) remain at risk for progressive neurological deterioration. Phenotypes vary in their pathology, ranging from axonal degeneration to inflammatory demyelination. The severity of symptoms is poorly explained by conventional imaging. OBJECTIVE: To test the hypothesis that neurochemistry in normal-appearing brains differs in adult phenotypes of X-ALD and that neurochemical changes correlate with the severity of symptoms. PATIENTS AND METHODS: Using a 7-Tesla scanner, we performed structural and proton magnetic resonance spectroscopic imaging in 13 adult patients with X-ALD: 4 patients with adult cerebral ALD, 5 patients with adrenomyeloneuropathy (AMN), and 4 female heterozygotes. Nine healthy controls were included. RESULTS: Among adult X-ALD phenotypes, the myo-inositol to creatine ratio was 46% higher and the choline to creatine ratio was 21% higher in normal-appearing white matter of those with adult cerebral ALD compared with those with AMN (P < .05). Both N-acetylaspartate to creatine (P = .03) and glutamate to creatine (P = .04) ratios were lower in AMNpatients than in controls. There were no significant differences between patients with AMN and female heterozygotes. In the cortex, patients with adult cerebral ALD had lower N-acetylaspartate to creatine ratios compared with female heterozygotes and controls (P = .02). The global myo-inositol to creatine ratio demonstrated a significant association with Expanded Disability Status Scale score (Spearman rho = 0.66, P = .04). CONCLUSIONS: Seven-Tesla proton magnetic resonance spectroscopic imaging reveals differences in the neurochemistry of adult cerebral ALD but cannot distinguish AMNpatients from female heterozygotes. Myo-inositol to creatine ratio correlates with the severity of the symptoms and may be a meaningful biomarker in adult X-ALD.
Authors: A Fatemi; P B Barker; A M Uluğ; L M Nagae-Poetscher; N J Beauchamp; A B Moser; G V Raymond; H W Moser; S Naidu Journal: Neurology Date: 2003-04-22 Impact factor: 9.910
Authors: Kerry A Broom; Daniel C Anthony; John P Lowe; Julian L Griffin; Helen Scott; Andrew M Blamire; Peter Styles; V Hugh Perry; Nicola R Sibson Journal: Neurobiol Dis Date: 2007-04-05 Impact factor: 5.996
Authors: Victor V Dyakin; Yuanxin Chen; Craig A Branch; Aidong Yuan; Mala Rao; Asok Kumar; Corrinne M Peterhoff; Ralph A Nixon Journal: Neuroimage Date: 2010-03-11 Impact factor: 6.556
Authors: Casey A Maguire; Servio H Ramirez; Steven F Merkel; Miguel Sena-Esteves; Xandra O Breakefield Journal: Neurotherapeutics Date: 2014-10 Impact factor: 7.620
Authors: Ian Cheong; Małgorzata Marjańska; Dinesh K Deelchand; Lynn E Eberly; David Walk; Gülin Öz Journal: Neurochem Res Date: 2017-04-03 Impact factor: 3.996
Authors: E-M Ratai; S Pilkenton; J He; R Fell; J P Bombardier; C-G Joo; M R Lentz; W-K Kim; T H Burdo; P Autissier; L Annamalai; E Curran; S P O'Neil; S V Westmoreland; K C Williams; E Masliah; R Gilberto González Journal: J Med Primatol Date: 2011-04-04 Impact factor: 0.667
Authors: Gilbert Hangel; Bernhard Strasser; Michal Považan; Stephan Gruber; Marek Chmelík; Martin Gajdošík; Siegfried Trattnig; Wolfgang Bogner Journal: NMR Biomed Date: 2015-09-15 Impact factor: 4.044
Authors: Siegfried Trattnig; Elisabeth Springer; Wolfgang Bogner; Gilbert Hangel; Bernhard Strasser; Barbara Dymerska; Pedro Lima Cardoso; Simon Daniel Robinson Journal: Neuroimage Date: 2016-11-13 Impact factor: 6.556
Authors: Arne Lauer; Xiao Da; Mikkel Bo Hansen; Gregoire Boulouis; Yangming Ou; Xuezhu Cai; Afonso Liberato Celso Pedrotti; Jayashree Kalpathy-Cramer; Paul Caruso; Douglas L Hayden; Natalia Rost; Kim Mouridsen; Florian S Eichler; Bruce Rosen; Patricia L Musolino Journal: Brain Date: 2017-12-01 Impact factor: 13.501